Financial news scored by AI. No noise, no delay. Latest: AT&S Reports Record Q2 Growth and Profitability (Impact: +65). OpenBell scores breaking market news for potential price impact, so you can see why it matters, not just that it happened.
Financial News with AI Impact Scores
Get real-time financial news with AI-powered impact analysis delivered through Discord
Today's Market Overview
openbell provides real-time news intelligence for smarter trades. Latest stories cover Industrials, Healthcare sectors. Top story: "AT&S Reports Record Q2 Growth and Profitability" with +65 impact score.
Join our Discord community for real-time alerts and discussions.
AT&S reported second-quarter revenue above EUR 680 million on November 5, 2026, describing the period as a record for growth and profitability. Management attributed the results primarily to its substrate business. The company confirmed its full-year guidance and said its multi-year capacity expansion program remains on schedule, supported by strong customer demand and tight supply.
Genmab reported revenue of $3.24 billion for the nine months ended September 30, 2026, up 22% year over year, with royalty revenue of $2.699 billion and EPKINLY/TEPKINLY global sales of $491 million. Operating profit was $986 million and net profit was $698 million. The company maintained its previously issued 2026 financial guidance and increased investment in its pipeline, including advancing Rina-S and petosemtamab.
